ASTRAZENECA PHARMA INDIA LTD.

AstraZeneca Pharma India Ltd has received a stay from the Hon'ble High Court of Delhi on a demand notice issued by the National Pharmaceutical Pricing Authority (NPPA). The NPPA had alleged overcharging for Betaloc-50 (Metoprolol 50 mg tablets) between June and July 2016. The High Court has stayed the operation of the demand notice until February 10, 2027, provided the company deposits 15% of the demanded amount with the Registrar General of the Court. This action is in response to the company challenging the NPPA's demand for recovery of alleged overcharged amounts.

AstraZeneca Pharma India Ltd has received an Environmental, Social, and Governance (ESG) rating of 57 from CRISIL ESG Ratings & Analytics Limited. The rating was assigned based on publicly available information, and the company has not engaged CRISIL ESG Ratings for this assessment. CRISIL independently prepared the reporting. This independent rating provides an external perspective on the company's ESG performance.

AstraZeneca Pharma India Ltd. announced its financial results for the quarter ended June 30, 2026, reporting a 30% year-on-year growth in total revenue from operations to INR 6,828 Mn. The company's performance was driven by its core therapy areas: Oncology, Biopharmaceuticals (CVRM and R&I), and Rare Disease. Key financial highlights include a Profit before exceptional item and tax of INR 510 Mn and Profit after exceptional item and tax of INR 507 Mn. The company also received regulatory approvals for Acalabrutinib for Chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL) and Mantle cell lymphoma (MCL), and for Trastuzumab deruxtecan in HER2-positive breast cancer. Strategic initiatives include an MoU with the Government of Telangana for AI-enabled lung cancer screening and the launch of the K+ Connect initiative for hyperkalaemia management.

AstraZeneca Pharma India's standalone Q1 FY27 (quarter ended June 30, 2026) revenue from operations rose 29.7% YoY to ₹682.8 Cr (₹526.3 Cr a year ago) and 18.0% QoQ (₹578.6 Cr in Q4 FY26), matching the company's own reported "30% growth" claim. But profit after tax fell 32.1% YoY to ₹37.9 Cr (₹55.8 Cr in Q1 FY26) and 15.5% QoQ (₹44.9 Cr in Q4 FY26), with EPS down to ₹15.17 from ₹22.33 a year earlier. The divergence between strong top-line growth and a shrinking bottom line is the story of the quarter. Operating profitability (profit before exceptional items and tax, as % of revenue) nearly halved to 7.5% from 15.3% a year ago and 10.3% last quarter; net margin fell to 5.6% from 10.4% YoY. The squeeze sits mainly on cost of goods and opex: purchase of stock-in-trade plus inventory movement together consumed ₹4,472 Mn of the ₹6,410 Mn total expense base, up sharply from ₹2,859 Mn a year ago, while employee benefit expense rose 22.8% YoY to ₹791.6 Mn — both outpacing revenue growth. A small exceptional charge of ₹2.4 Mn (site-exit related, Note 5) was booked, similar to ₹3.6 Mn a year ago, so it barely moves the growth math either way. Segment-wise, Oncology revenue grew 26% YoY to ₹464.9 Cr, Biopharmaceuticals (CVRM, R&I, V&I) grew 36% to ₹161.9 Cr, and Rare Diseases surged 35x to ₹14.4 Cr off a small base. Management gives no formal FY27 guidance or margin target on record, so this print cannot be measured against a stated company outlook. Our pre-result preview had pegged Q1 revenue at just ₹290-310 Cr and PAT at ₹24-28 Cr with an 8-9% margin watch band; actual revenue and PAT both came in well above that range, but the preview bar looks stale against the company's own FY26 run-rate (₹520-580 Cr/quarter), so the "beat" reflects a low preview baseline more than genuine outperformance — meanwhile actual NPM of 5.6% missed the preview's 8-9% margin watch, consistent with the compression flagged. Separately, the Board approved Arun Krishna's appointment as Additional Director (effective Aug 17, 2026) and redesignated outgoing CFO Bhavana Agrawal — who resigned July 21, 2026 for a regional AstraZeneca role — from Executive to Non-Executive Director effective September 1, 2026. Post quarter-end, the company also received a ₹148.6 Cr NPPA demand notice alleging overcharging on a respiratory drug sold between May 2016 and November 2025; management is contesting it and has booked it as a contingent liability with no provision. CFO Bhavana Agrawal said the 30% revenue growth "builds on a strong track record of consistent double-digit growth," but her quoted remarks did not address the margin decline. With operating margin down nearly 800 bps YoY and a large contingent NPPA liability outstanding, the next print will need to show whether cost pressure eases and whether the Enhertu/Fasenra oncology launches (approved Aug 7-8 and Jul 16, 2026 respectively) turn into margin-accretive volume, alongside continuity once Agrawal's CFO transition completes August 31, 2026.

AstraZeneca Pharma India Ltd announced on August 7, 2026, that it has received approval from the Central Drugs Standard Control Organization (CDSCO) to import for sale and distribution of Trastuzumab Deruxtecan (Enhertu®) 100mg/5mL lyophilized powder for concentrate for solution for infusion. This approval is for an additional indication: the adjuvant treatment of adult patients with HER2-positive breast cancer who have residual invasive disease after neoadjuvant treatment. This paves the way for the marketing of Enhertu® in India for this specific indication, subject to further statutory approvals.

AstraZeneca Pharma India Ltd has announced that its Board of Directors will convene on August 10, 2026. The primary agenda item for this meeting is to consider and approve the un-audited financial results for the quarter ended June 30, 2026. Additionally, the company confirmed that the trading window for designated persons will remain closed from June 16, 2026, to August 12, 2026, inclusive, in compliance with SEBI regulations on insider trading.

AstraZeneca Pharma India Ltd has received a demand notice from the National Pharmaceutical Pricing Authority (NPPA) for alleged overcharging under the Drugs (Prices Control) Order, 2013. The notice, dated July 29, 2026, pertains to Symbicort Turbuhaler and demands ₹1,48,65,83,590, inclusive of interest calculated up to August 20, 2026. This amount is payable within 30 days. The company is currently evaluating the notice and considering appropriate legal actions. The alleged overcharging relates to the period from May 2016 to November 2025.

AstraZeneca Pharma India Ltd has received a demand notice from the National Pharmaceutical Pricing Authority (NPPA) for alleged overcharging of ₹79,97,457, including interest, on Betaloc-50 (Metoprolol 50 mg tablets). The NPPA alleges that the company sold the drug at a price higher than the notified ceiling price and failed to implement revised ceiling prices on existing stocks. The overcharging is alleged to have occurred between June and July 2016. The company is reviewing the notice and will take appropriate legal steps.

AstraZeneca Pharma India Ltd has received approval from the Central Drugs Standard Control Organization (CDSCO) to import for sale and distribution of Trastuzumab Deruxtecan (Enhertu®) for an additional indication. This approval is for the neoadjuvant treatment of adult patients with HER2-positive Stage II or III breast cancer, when used in combination with trastuzumab and pertuzumab. The receipt of this permission allows for the marketing of Enhertu® in India for this specific indication, pending any further statutory approvals. This marks a significant step in expanding the therapeutic options for breast cancer patients in India.

AstraZeneca Pharma India Ltd announced its Board of Directors has recommended a final dividend of ₹36 per share for the financial year 2025-26. This recommendation is subject to shareholder approval at the 47th Annual General Meeting scheduled for August 10, 2026. The record date for determining dividend entitlement is July 31, 2026. The company also detailed the tax deduction at source (TDS) procedures for the dividend, which will be taxable in the hands of shareholders from FY2020-21 onwards. Specific TDS rates and documentation requirements are outlined for resident and non-resident shareholders, including provisions for PAN holders, non-PAN holders, and those eligible for Double Tax Avoidance Treaty (DTAA) benefits.